NASDAQ$ALEC
Alector Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Alector reported its financial results for Q3 2022 and provided a business update.
Alector reported a net loss of $46.1 million for the third quarter of 2022, with cash, cash equivalents, and investments totaling $758.3 million as of September 30, 2022, expected to fund operations through 2024. The company also progressed enrollment in clinical trials for latozinemab (AL001) and AL002, and initiated a Phase 1 trial for AL044.
- Enrollment is progressing in the INFRONT-3 Phase 3 pivotal study for latozinemab (AL001) and in the INVOKE-2 Phase 2 study for AL002.
- The company initiated a first-in-human Phase 1 trial of AL044, a novel microglia immune checkpoint therapy for Alzheimer’s disease.
- Cash, cash equivalents, and investments totaled $758.3 million, providing a runway through 2024.
- Alector anticipates submitting an IND for its AL009 innate immuno-oncology program before the end of the year.
Headline financials
Revenue & EPS history
Alector · Revenue · Quarterly
$14.9M
Revenue by segment
Alector · $14.9M total across 1 segment · Q3 2022
- Collaboration Revenue$14.9M-91.9%100.0%
Forward guidance
Alector anticipates biomarker data from the AL044 healthy volunteer study and completion of enrollment in the INVOKE-2 study in 2023, and expects cash to fund operations through 2024.
Tailwinds
- The company expects to report follow-up data from the INFRONT-2 Phase 2 clinical trial of latozinemab in frontotemporal dementia patients with a C9orf72 genetic mutation (FTD-C9orf72) in 2023.
- Alector will present a poster with data from the Phase 1 trial of AL101 in healthy volunteers at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference.
- Safety and biomarker data from the AL044 study are anticipated in 2023.
- Alector anticipates submitting an IND for its AL009 innate immuno-oncology program before the end of the year.
- Management anticipates that cash, cash equivalents, and investments will be sufficient to fund current operations through 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.1%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-5.5%
Avg return
30 days after
52%
15 / 29 earnings
Positive
+32.9%
Q2 2023
Best reaction
-18.4%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -16.0% | -36.6% | |
| Q4 2025 | +7.1% | -11.7% | -16.3% | |
| Q3 2025 | +4.1% | +8.4% | -2.8% | |
| Q1 2025 | +4.2% | +7.4% | +23.8% | |
| Q4 2024 | -3.5% | -15.4% | -25.0% | |
| Q3 2024 | +12.8% | +21.3% | -56.8% | |
| Q2 2024 | +0.8% | +0.9% | -4.2% | |
| Q1 2024 | -1.9% | +1.7% | -17.7% | |
| Q4 2023 | +7.9% | +14.4% | -7.1% | |
| Q3 2023 | -2.6% | -17.7% | +6.0% | |
| Q2 2023 | +32.9% | +12.4% | -15.6% | |
| Q1 2023 | +13.0% | +20.6% | +8.5% | |
| Q4 2022 | +0.9% | -9.5% | -30.3% | |
| Q3 2022 | -18.4% | +3.1% | +3.1% | |
| Q2 2022 | +16.3% | +12.7% | -6.9% | |
| Q1 2022 | -12.7% | -20.0% | -11.9% | |
| Q4 2021 | +1.9% | -1.3% | -7.8% | |
| Q3 2021 | +2.3% | +4.1% | -20.7% | |
| Q2 2021 | +9.5% | +9.0% | +10.1% | |
| Q1 2021 | -7.8% | -12.4% | +6.1% | |
| Q4 2020 | -4.7% | -10.7% | -14.3% | |
| Q3 2020 | +0.4% | +7.2% | +25.2% | |
| Q2 2020 | -6.9% | -7.4% | -13.5% | |
| Q1 2020 | -5.0% | +0.3% | +3.7% | |
| Q4 2019 | -1.5% | -4.4% | +0.8% | |
| Q3 2019 | -6.1% | -4.2% | +19.5% | |
| Q2 2019 | -1.7% | -18.0% | +9.4% | |
| Q1 2019 | +4.9% | +1.3% | +0.2% | |
| Q4 2018 | -8.6% | -3.5% | +10.8% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro